Polyendocrine Metabolic Ovarian Syndrome (PMOS)

Researchers and global medical experts have announced that Polycystic Ovary Syndrome (PCOS), a major cause of infertility affecting nearly 170 million women worldwide, will be renamed as “Polyendocrine Metabolic Ovarian Syndrome” (PMOS).

The new name was adopted by an international coalition of patients, clinicians and medical organisations, and was presented alongside a report published in The Lancet during the European Congress of Endocrinology in Prague.

The renaming reflects the understanding that the condition is a multisystem disorder involving endocrine, metabolic, reproductive, psychological and dermatological complications, rather than only ovarian abnormalities.

PMOS highlights broader health risks associated with the condition, including obesity, abnormal blood sugar levels, Type 2 Diabetes, hypertension, dyslipidemia, fatty liver disease, cardiovascular disease and sleep apnoea, while the transition to the new terminology will occur gradually over the next three years.